September 2014 Volume 10, Issue 9
Volume 10, Issue 9 | September 2014
September 2014
In this Issue
Feature
ASHG 2014 Preview: Shining a light on human genetics in sunny San Diego
Reportedly the largest human genetics meeting and exposition in the world, the ASHG gathering from Oct. 18 to 22 will cover ethics in genomics, advances in sequencing and much else, attracting more than 6,500 scientific attendees and featuring well over 200 exhibiting companiesEditor's Focus
Much ado about Ebola
There is no doubt that Ebola is a monumental problem, and it's a notable part of our September issue coverage. But there's also been a lot of excessive fear and hype as well, which has perhaps made the disease look like something out of an apocalyptic novel or film. On the bright side, the increased attention seems to have mobilized many pharmas, biotechs, government agencies and others to increase the pace of Ebola diagnostics and therapies, which could be welcome relief to the people most at risk of the disease.Commentary
Out of Order: The undiscovered country
Off- label prescribing of pharmaceutical products by physicians has a long history and even some notable successes, but the practice also poses many challenges and risks.Patent Docs: FDA releases draft guidances on biosimilars
The U.S. Food and Drug Administration was been busy in spring 2014, releasing two new guidances (in May and August) relating to its evolving standards for satisfying the biosimilarity requirements of the Biologics Price Competition and Innovation Act.Q&A
Q&A: Taking the measure of ‘omics results in health science and personalized medicine
DDNews asks Dr. Rohit Khanna, vice president of worldwide marketing for the Waters Division of Waters Corp., to share his views on the advances in mass spectrometry and how they are impacting healthcare deliveryClinical Trials
RedHill options Phase 2 pancreatic cancer drug
RP101 has been granted Orphan Drug designation for the adjunct treatment of pancreatic cancer by FDA and EMAEasy to take
Weekly, ready-to-use drug could be good news for type 2 diabeticsExciting results from exon-skipping
Sarepta’s eteplirsen stabilizes lung function, slows mobility loss in Duchenne patientsDupilumab’s skin story
Investigative monoclonal antibody shows potential for eczema reliefOhr presents two Squalamine Phase 2 data sets
Trial data for retinal vein occlusion and wet age-related macular degeneration detailed at 2014 ASRS meetingXention commences first Phase 2 study of XEN-D0103 in atrial fibrillation
Xention Ltd. recently announced that the Phase 2 development of its lead atrial fibrillation (AF) program is underwayPreclinical
Roche puts its back into fighting SMA
Oral treatment for spinal muscular atrophy appears effective in miceFinding the right channel
Xention’s atrial fibrillation research receives funding from British governmentSmoke stopper
Addex drug achieves positive results in preclinical model of nicotine addictionEpizyme debuts preclinical EZH2 inhibitor data at ASH meeting
EPZ-6438 has engendered partial response in two non- Hodgkin lymphoma patients; maximum tolerated dose not yet reachedGSOs and TLRs make antisense work
Idera Pharmaceuticals and collaborators publish promising preclinical data targeting microRNA with gene-silencing oligonucleotide technologyResearch & Development
Delivering the genes
Scripps Research Institute scientists find that cancer drug rapamycin may help bypass blood stem cell defensesInterferon may be key to fighting Ebola
Finding provides framework for new drug development effortsUnderstanding the ways of pathogenic harm
NIAID grant supports infectious disease research at the Institute for Genome Sciences to the tune of $15.2 millionA toolkit for the genome
Horizon Discovery Group licenses Stanford University technology to enhance gene editingA deal on peptides
Zealand Pharma and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicinesDiscovery
Library renewal
Collaboration renewal maintains collection of more than 200,000 compounds for investigationSanford- Burnham sets sights on MEF2
Transcription factor thought to be a therapeutic target for Alzheimer’s, Parkinson’s diseaseLess pain, more gain
Scripps scientists in Florida discover new targets to reduce side effects in treating breast cancerDiagnostics
Hope springs eternal
NIH names new clinical sites for Undiagnosed Diseases Network and provides $43 millionTapping CDx expertise
Ventana signs companion diagnostic test agreements with Merck KGaA and QuintilesFlushing out the fatty fog
Researchers build off CLARITY technique to make bodies ‘transparent’ for 3D imagingFDA green-lights DoD Ebola diagnostic
Assay will aid in detecting infection with Ebola Zaire virus in individuals at riskBusiness & Government Policy
A deep breath for an $8.3-billion plunge
Roche and InterMune enter merger agreement aimed at expanding Roche’s respiratory portfolioRoche snaps up Santaris
Deal gains Roche access to Santaris’ platform for RNA-targeted therapeuticsVenter gains a key human asset
Google’s Franz Och joins Human Longevity as chief data scientistThree-in-one combo gets two green lights
ViiV Healthcare receives FDA approval and EU marketing authorization for Triumeq in treatment of HIV-1 infectionFDA approves Ryanodex for treatment of malignant hyperthermia
Eagle Pharmaceuticals Inc. announced this summer that the U.S. Food and Drug Administration had approved Ryanodex
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
A closer look at the tumor microenvironment
New technologies are allowing researchers to delve deeper into the complex tumor landscape.
Exploring stain-free western blotting
Researchers can achieve seamless western blot experiments by implementing advancements in stain-free technology, normalization methods, and compliance integration.
Streamlining biopharmaceutical analysis with digital solutions
Discover how digitization improves data integrity and accelerates decision-making in biotherapeutics development.
